Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan's Ministry To Support Clinical Trial Contract Business

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Economy, Trade and Industry began to take measures to support clinical trial contract business. The measures aim to establish a market where research technology and services can be freely exchanged, and to foster an environment where service providers, users and intermediaries can easily participate. According to the ministry, currently in areas of biology and medical device contact services, small- to mid-sized companies who have advanced technology are not benefiting fully from manufacturing on contract for big companies, and an environment where ideas will be protected and technology will be subjectively evaluated is needed. The ministry will organize an expert committee and expects a report due by February 2009. (Click here for more - Japanese language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel